ADARx Pharmaceuticals, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
ADARx Pharmaceuticals is a biopharmaceutical company developing RNA-targeted therapeutics, including small interfering RNA and antibody-oligonucleotide conjugates, to treat genetically defined diseases affecting the central nervous system, kidneys, and other organs.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LLCInsider | Buy | $10.07M | 592,593at $17.00 | Sep 28, 2026 |
| SR ONE CAPITAL MANAGEMENT, LLCInsider | Buy | $7.05M | 414,814at $17.00 | Sep 28, 2026 |
| George SimeonInsider | Buy | $10.07M | 592,593at $17.00 | Sep 28, 2026 |
| George SimeonInsider | Buy | $7.05M | 414,814at $17.00 | Sep 28, 2026 |
| Chimovits ErezDirector | Buy | $1.05M | 61,516at $17.00 | Sep 28, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $10.00M | 588,235at $17.00 | Sep 28, 2026 |
| GORDON CARL LDirector | Buy | $5.10M | 300,249at $17.00 | Sep 28, 2026 |
| GORDON CARL LDirector | Buy | $10.00M | 588,235at $17.00 | Sep 28, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $5.10M | 300,249at $17.00 | Sep 28, 2026 |
| GORDON CARL LDirector | Buy | $1.05M | 61,516at $17.00 | Sep 28, 2026 |
| ORBIMED ADVISORS LLCDirector | Buy | $1.05M | 61,516at $17.00 | Sep 28, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ADRX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.